Skip to main content
Top
Published in: Annals of Surgical Oncology 1/2020

Open Access 01-01-2020 | Gastric Cancer | Peritoneal Surface Malignancy

Gastric Cancer Peritoneal Carcinomatosis Risk Score

Authors: Liang Ji, MBA, MPH, Matthew J. Selleck, DO, John W. Morgan, DrPH, Jane Xu, BA, Blake D. Babcock, MD, David Shavlik, PhD, MSPH, Nathan R. Wall, PhD, William H. Langridge, PhD, Sharon S. Lum, MD, Carlos A. Garberoglio, MD, Mark E. Reeves, MD, PhD, Naveenraj Solomon, MD, Jukes P. Namm, MD, Maheswari Senthil, MD

Published in: Annals of Surgical Oncology | Issue 1/2020

Login to get access

Abstract

Background

Gastric cancer (GC) peritoneal carcinomatosis (PC) is associated with a poor prognosis. Although grade, histology, and stage are associated with PC, the cumulative risk of PC when multiple risk factors are present is unknown. This study aimed to develop a cumulative GCPC risk score based on individual demographic/tumor characteristics.

Methods

Patient-level data (2004–2014) from the California Cancer Registry were reviewed by creating a keyword search algorithm to identify patients with gastric PC. Multivariable logistic regression was used to assess demographic/tumor characteristics associated with PC in a randomly selected testing cohort. Scores were assigned to risk factors based on beta coefficients from the logistic regression result, and these scores were applied to the remainder of the subjects (validation cohort). The summed scores of each risk factor formed the total risk score. These were grouped, showing the percentages of patients with PC.

Results

The study identified 4285 patients with gastric adenocarcinoma (2757 males, 64.3%). The median age of the patients was 67 years (interquartile range [IQR], 20 years). Most of the patients were non-Hispanic white (n = 1748, 40.8%), with proximal (n = 1675, 39.1%) and poorly differentiated (n = 2908, 67.9%) tumors. The characteristics most highly associated with PC were T4 (odds ratio [OR], 3.12; 95% confidence interval [CI], 2.19–4.44), overlapping location (OR 2.27; 95% CI 1.52–3.39), age of 20–40 years (OR 3.42; 95% CI 2.24–5.21), and Hispanic ethnicity (OR 1.86; 95% CI 1.36–2.54). The demographic/tumor characteristics used in the risk score included age, race/ethnicity, T stage, histology, tumor grade, and location. Increasing GCPC score was associated with increasing percentage of patients with PC.

Conclusion

Based on demographic/tumor characteristics in GC, it is possible to distinguish groups with varying odds for PC. Understanding the risk for PC based on the cumulative effect of high-risk features can help clinicians to customize surveillance strategies and can aid in early identification of PC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRef
3.
go back to reference Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival, and risk factors. Int J Cancer. 2014;134:622–8.CrossRef Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival, and risk factors. Int J Cancer. 2014;134:622–8.CrossRef
4.
go back to reference Seyfried F, von Rahden BH, Miras AD, et al. Incidence, time course, and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin: a longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer. 2015;15:73.CrossRef Seyfried F, von Rahden BH, Miras AD, et al. Incidence, time course, and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin: a longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer. 2015;15:73.CrossRef
5.
go back to reference D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240:808–16.CrossRef D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240:808–16.CrossRef
6.
go back to reference Roviello F, Marrelli D, de Manzoni G, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90:1113–9.CrossRef Roviello F, Marrelli D, de Manzoni G, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90:1113–9.CrossRef
7.
go back to reference Spolverato G, Ejaz A, Kim Y, et al. Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. J Am Coll Surg. 2014;219:664–75.CrossRef Spolverato G, Ejaz A, Kim Y, et al. Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. J Am Coll Surg. 2014;219:664–75.CrossRef
8.
go back to reference Yang XJ, Li Y, Yonemura Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: results from a Chinese center. J Surg Oncol. 2010;101:457–64.CrossRef Yang XJ, Li Y, Yonemura Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: results from a Chinese center. J Surg Oncol. 2010;101:457–64.CrossRef
9.
go back to reference Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.CrossRef Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.CrossRef
10.
go back to reference Sayag-Beaujard AC, Francois Y, Glehen O, et al. Intraperitoneal chemo-hyperthermia with mitomycin C for gastric cancer patients with peritoneal carcinomatosis. Anticancer Res. 1999;19:1375–82.PubMed Sayag-Beaujard AC, Francois Y, Glehen O, et al. Intraperitoneal chemo-hyperthermia with mitomycin C for gastric cancer patients with peritoneal carcinomatosis. Anticancer Res. 1999;19:1375–82.PubMed
11.
go back to reference Yonemura Y, Canbay E, Endou Y, et al. Peritoneal cancer treatment. Expert Opin Pharmacother. 2014;15:623–36.CrossRef Yonemura Y, Canbay E, Endou Y, et al. Peritoneal cancer treatment. Expert Opin Pharmacother. 2014;15:623–36.CrossRef
12.
go back to reference Sugarbaker PH, Yu W, Yonemura Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol. 2003;21:233–48.CrossRef Sugarbaker PH, Yu W, Yonemura Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol. 2003;21:233–48.CrossRef
14.
go back to reference Fritz A PC, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S. International classification of diseases for oncology, 3rd edn. World Health Organization, Geneva, 2000. Fritz A PC, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S. International classification of diseases for oncology, 3rd edn. World Health Organization, Geneva, 2000.
16.
go back to reference Ohi M, Mori K, Toiyama Y, et al. Preoperative prediction of peritoneal metastasis in gastric cancer as an indicator for neoadjuvant treatment. Anticancer Res. 2015;35:3511–8.PubMed Ohi M, Mori K, Toiyama Y, et al. Preoperative prediction of peritoneal metastasis in gastric cancer as an indicator for neoadjuvant treatment. Anticancer Res. 2015;35:3511–8.PubMed
17.
18.
go back to reference Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Sour Code Biol Med. 2008;3:2–7. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Sour Code Biol Med. 2008;3:2–7.
19.
go back to reference Inc SI. SAS/STAT 14.1 User’s Guide. SAS Institute Inc., Cary, NC, 2015. Inc SI. SAS/STAT 14.1 User’s Guide. SAS Institute Inc., Cary, NC, 2015.
21.
go back to reference Merchant SJ, Kim J, Choi AH, Sun V, Chao J, Nelson R. A rising trend in the incidence of advanced gastric cancer in young Hispanic men. Gastric Cancer. 2017;20:226–34.CrossRef Merchant SJ, Kim J, Choi AH, Sun V, Chao J, Nelson R. A rising trend in the incidence of advanced gastric cancer in young Hispanic men. Gastric Cancer. 2017;20:226–34.CrossRef
22.
go back to reference Chang ET, Gomez SL, Fish K, et al. Gastric cancer incidence among Hispanics in California: patterns by time, nativity, and neighborhood characteristics. Cancer Epidemiol Biomark Prev. 2012;21:709–19.CrossRef Chang ET, Gomez SL, Fish K, et al. Gastric cancer incidence among Hispanics in California: patterns by time, nativity, and neighborhood characteristics. Cancer Epidemiol Biomark Prev. 2012;21:709–19.CrossRef
23.
go back to reference Gupta S, Tao L, Murphy JD, et al. Race/ethnicity-, socioeconomic status-, and anatomic subsite-specific risks for gastric cancer. Gastroenterology. 2019;156:59–62 e54.CrossRef Gupta S, Tao L, Murphy JD, et al. Race/ethnicity-, socioeconomic status-, and anatomic subsite-specific risks for gastric cancer. Gastroenterology. 2019;156:59–62 e54.CrossRef
24.
go back to reference Rajabi B, Corral JC, Hakim N, Mulla ZD. Descriptive epidemiology of gastric adenocarcinoma in the state of Texas by ethnicity: Hispanic versus white non-Hispanic. Gastric Cancer. 2012;15:405–13.CrossRef Rajabi B, Corral JC, Hakim N, Mulla ZD. Descriptive epidemiology of gastric adenocarcinoma in the state of Texas by ethnicity: Hispanic versus white non-Hispanic. Gastric Cancer. 2012;15:405–13.CrossRef
25.
go back to reference Dong E, Duan L, Wu BU. Racial and ethnic minorities at increased risk for gastric cancer in a regional U.S. population study. Clin Gastroenterol Hepatol. 2017;15:511–7.CrossRef Dong E, Duan L, Wu BU. Racial and ethnic minorities at increased risk for gastric cancer in a regional U.S. population study. Clin Gastroenterol Hepatol. 2017;15:511–7.CrossRef
26.
go back to reference Bohner H, Zimmer T, Hopfenmuller W, Berger G, Buhr HJ. Detection and prognosis of recurrent gastric cancer: is routine follow-up after gastrectomy worthwhile? Hepatogastroenterology. 2000;47:1489–94.PubMed Bohner H, Zimmer T, Hopfenmuller W, Berger G, Buhr HJ. Detection and prognosis of recurrent gastric cancer: is routine follow-up after gastrectomy worthwhile? Hepatogastroenterology. 2000;47:1489–94.PubMed
27.
go back to reference Kodera Y, Ito S, Yamamura Y, et al. Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol. 2003;10:898–902.CrossRef Kodera Y, Ito S, Yamamura Y, et al. Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol. 2003;10:898–902.CrossRef
28.
go back to reference Eom BW, Ryu KW, Lee JH, et al. Oncologic effectiveness of regular follow-up to detect recurrence after curative resection of gastric cancer. Ann Surg Oncol. 2011;18:358–64.CrossRef Eom BW, Ryu KW, Lee JH, et al. Oncologic effectiveness of regular follow-up to detect recurrence after curative resection of gastric cancer. Ann Surg Oncol. 2011;18:358–64.CrossRef
29.
go back to reference Laks S, Meyers MO, Kim HJ. Surveillance for gastric cancer. Surg Clin N Am. 2017;97:317–31.CrossRef Laks S, Meyers MO, Kim HJ. Surveillance for gastric cancer. Surg Clin N Am. 2017;97:317–31.CrossRef
30.
go back to reference Zhou R, Wu Z, Zhang J, et al. Clinical significance of accurate identification of lymph node status in distant metastatic gastric cancer. Oncotarget. 2016;7:1029–41.PubMed Zhou R, Wu Z, Zhang J, et al. Clinical significance of accurate identification of lymph node status in distant metastatic gastric cancer. Oncotarget. 2016;7:1029–41.PubMed
Metadata
Title
Gastric Cancer Peritoneal Carcinomatosis Risk Score
Authors
Liang Ji, MBA, MPH
Matthew J. Selleck, DO
John W. Morgan, DrPH
Jane Xu, BA
Blake D. Babcock, MD
David Shavlik, PhD, MSPH
Nathan R. Wall, PhD
William H. Langridge, PhD
Sharon S. Lum, MD
Carlos A. Garberoglio, MD
Mark E. Reeves, MD, PhD
Naveenraj Solomon, MD
Jukes P. Namm, MD
Maheswari Senthil, MD
Publication date
01-01-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 1/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07624-0

Other articles of this Issue 1/2020

Annals of Surgical Oncology 1/2020 Go to the issue